Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Kasper Broedbaek x
Clear All Modify Search
Steen J. Bonnema Departments of Endocrinology, Odense University Hospital, Odense

Search for other papers by Steen J. Bonnema in
Google Scholar
PubMed
Close
,
Elisabeth S. Stovgaard Laboratory of Clinical Pharmacology Q7642, Rigshospitalet

Search for other papers by Elisabeth S. Stovgaard in
Google Scholar
PubMed
Close
,
Søren Fast Departments of Endocrinology, Odense University Hospital, Odense

Search for other papers by Søren Fast in
Google Scholar
PubMed
Close
,
Kasper Broedbaek Laboratory of Clinical Pharmacology Q7642, Rigshospitalet

Search for other papers by Kasper Broedbaek in
Google Scholar
PubMed
Close
,
Jon T. Andersen Laboratory of Clinical Pharmacology Q7642, Rigshospitalet

Search for other papers by Jon T. Andersen in
Google Scholar
PubMed
Close
,
Allan Weimann Laboratory of Clinical Pharmacology Q7642, Rigshospitalet

Search for other papers by Allan Weimann in
Google Scholar
PubMed
Close
,
Peter Grupe Departments of Nuclear Medicine, Odense University Hospital, Odense

Search for other papers by Peter Grupe in
Google Scholar
PubMed
Close
,
Laszlo Hegedüs Departments of Endocrinology, Odense University Hospital, Odense

Search for other papers by Laszlo Hegedüs in
Google Scholar
PubMed
Close
, and
Henrik E. Poulsen Laboratory of Clinical Pharmacology Q7642, Rigshospitalet
Department of Clinical Pharmacology, Bispebjerg Hospital
Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Henrik E. Poulsen in
Google Scholar
PubMed
Close

Background: Little is known about the whole body oxidative stress burden following radioactive iodine (<sup>131</sup>I) therapy of thyroid diseases. Methods: We studied 17 patients with benign nodular goiter treated with <sup>131</sup>I therapy. The targeted thyroid dose was 50 Gy in 11 patients pretreated with 0.1 mg of recombinant human TSH (rhTSH). In 6 patients, the applied thyroid dose was 100 Gy without rhTSH prestimulation. Well-established biomarkers of oxidative stress to RNA (8-oxo-7,8-dihydroguanosine; 8-oxoGuo) and DNA (8-oxo-7,8-dihydro-2'-deoxyguanosine; 8-oxodG) were measured in freshly voided morning urine (normalized against the creatinine concentration) at baseline, and 7 and 21 days after rhTSH (not followed by <sup>131</sup>I), and 7 and 21 days after <sup>131</sup>I therapy, respectively. Results: The baseline urinary excretions of 8-oxoGuo and 8-oxodG were 2.20 ± 0.84 and 1.63 ± 0.70 nmol/mmol creatinine, respectively. We found no significant changes in the excretion of any of the metabolites, neither after rhTSH stimulation alone nor after <sup>131</sup>I therapy. Also, no significant differences were found between the rhTSH group (low dose, median <sup>131</sup>I: 152 MBq) and the non-rhTSH group (high dose, median <sup>131</sup>I: 419 MBq; 8-oxoGuo: p = 0.66, 8-oxodG: p = 0.71). Conclusion: Systemic oxidative stress, as detected by nucleic acids metabolites in the urine, is not increased after thyroid stimulation with 0.1 mg of rhTSH, or after <sup>131</sup>I therapy. Our method cannot quantify the oxidative stress induced locally in the thyroid gland, but the study supports that <sup>131</sup>I therapy of benign nodular goiter carries no or only a minute risk of developing subsequent malignancies. It remains to be explored whether our findings also apply to hyperthyroid disorders.

Free access